Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Prostatic Neoplasms 3Melanoma 3Lymphoma, Non-Hodgkin 3Recurrence 2Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell 2Lymphoma 2Neoplasm Metastasis 1Lymphatic Diseases 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Burkitt Lymphoma 1Breast Neoplasms 1

Interventions

tisagenlecleucel 8Cyclophosphamide 7fludarabine 5blinatumomab 5aflibercept 4ibrutinib 2epratuzumab 2Vincristine 2Radioimmunodetection 2Methotrexate 2MLN 8237 2Inotuzumab Ozogamicin 2Dexamethasone 2tocilizumab 1tafasitamab 1siltuximab 1sepantronium 1ruxolitinib 1relatlimab 1pembrolizumab 1pegaspargase 1ontuxizumab 1obinutuzumab 1loncastuximab tesirine 1forodesine 1fludarabine phosphate 1fiu protein, E coli 1exatecan 1brexucabtagene autoleucel 1asparaginase erwinia chrysanthemi recombinant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Burkitt Lymphoma × sepantronium × Clear all
NCT05263583 2025-01-14

Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma

Cothera Bioscience, Inc

Phase 2 Active not recruiting
14 enrolled
Lymphoid

Burkitt Lymphoma, Lymphatic Diseases, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡